newsfilter
← Latest News
PR Newswire·

CTI BioPharma Reports Third Quarter 2022 Financial Results

– VONJO® (pacritinib) net product revenue of $18.2 million in the third quarter, a 48% increase compared to the second quarter – – Increase in sales reflects strong growth in new patient starts – – Oral presentation